IMPEL NEUROPHARMA INC (IMPL) Social Stream
IMPEL PHARMACEUTICALS INC (IMPL) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering IMPEL PHARMACEUTICALS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-16 | 3 | $55 | $32 | $42 | $0.241 | 17327.39% |
| 2022-03-25 | 3 | $55 | $32 | $39.666 | $0.241 | 16358.92% |
| 2022-05-17 | 3 | $55 | $31 | $43 | $0.241 | 17742.32% |
| 2022-08-16 | 2 | $55 | $31 | $43 | $0.241 | 17742.32% |
| 2022-10-13 | 2 | $55 | $24 | $39.5 | $0.241 | 16290.04% |
| 2022-11-15 | 2 | $55 | $5 | $30 | $0.241 | 12348.13% |
| 2023-01-23 | 2 | $40 | $5 | $22.5 | $0.241 | 9236.1% |
| 2023-03-27 | 2 | $40 | $4 | $22 | $0.241 | 9028.63% |
| 2023-04-17 | 2 | $40 | $2 | $21 | $0.241 | 8613.69% |
| 2023-04-24 | 1 | $40.001 | $40.001 | $40.001 | $0.241 | 16497.93% |
| 2023-05-15 | 1 | $40 | $40 | $40 | $0.241 | 16497.51% |
| NA | 1 | $NA | $NA | $NA | $0.241 | NA% |
The Trend in the Analyst Price Target
Over the past 14 months, IMPL's average price target has gone up $0.33.
Over the past 112 days, IMPL's average upside potential has been 1,670.48%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-23 | 2 | 40.000 | 5.000 | 22.500 | 3.60 | 525% |
| 2023-02-23 | 2 | 40.000 | 4.000 | 22.000 | 1.64 | 1241.46% |
| 2023-03-27 | 2 | 40.000 | 4.000 | 22.000 | 1.24 | 1674.19% |
| 2023-04-24 | 1 | 40.001 | 40.001 | 40.001 | 1.77 | 2159.94% |
| 2023-05-15 | 1 | 40.000 | 40.000 | 40.000 | 1.15 | 3378.26% |
IMPL Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 1 | 0 | 0 | 0 | 0 | 1 |
The Trend in the Broker Recommendations
Over the past 14 months, IMPL's average broker recommendation rating improved by 0.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for IMPL as an investment opportunity.
- To contextualize these metrics, consider that out of all US stocks, IMPEL PHARMACEUTICALS INC's upside potential (average analyst target price relative to current price) is greater than 1399.19% of them.
- IMPEL PHARMACEUTICALS INC's number of analysts covering the stock is greater than 57.51% of all US stocks.
- In the context of stocks in the small market cap category, IMPEL PHARMACEUTICALS INC's variance in analysts' estimates is lower than -809.04% of them.
- IMPEL PHARMACEUTICALS INC's average analyst price target is greater than 1102.84% of stocks in the small market cap category.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to IMPEL PHARMACEUTICALS INC are RAIN, HOWL, and VERA.
View All Top Stocks by Price Target
Make investment decisions regarding IMPL using the data that counts. Try POWR Ratings for free.